葵花药业：因涉及关联交易，公司及相关责任人被深交所下发监管函

Core Points - Recently, Kew Flower Pharmaceutical announced that it received a warning letter from the Heilongjiang Regulatory Bureau of the China Securities Regulatory Commission and a regulatory letter from the Shenzhen Stock Exchange [1] - The regulatory letter mentioned that in 2024, Kew Flower Pharmaceutical conducted procurement business with Shanghai Haiwei Biotechnology Co., Ltd. for an amount of 32.3836 million yuan, which accounted for 0.68% of the company's most recent audited net assets [1] - Gele Rui (Wuxi) Nutrition Technology Co., Ltd. is an affiliated legal entity of the company, and Shanghai Haiwei is a wholly-owned subsidiary of Gele Rui [1] - The transaction constitutes a related party transaction, and Kew Flower Pharmaceutical failed to follow the required review procedures and information disclosure obligations [1] - The announcement pointed out that the chairman, general manager, and board secretary of Kew Flower Pharmaceutical did not fulfill their due diligence obligations and bear primary responsibility for the violations [1]